Neumora Therapeutics: Downgrading After Navacaprant Development Setback (NASDAQ:NMRA)

NodeGuardian · 2026-04-10T14:07:54+00:00

Neumora Therapeutics has been downgraded to 'Hold' after the KOASTAL-1 MDD study's failure. Despite increased enrollment in KOASTAL-2 and KOASTAL-3 with results due in 2026, uncertainty remains. Promising results for NMRA-511 in Alzheimer's agitation are delayed until 2027.

NodeGuardian

2026-04-10 14:07:54

Abstract generation in progress

Neumora Therapeutics has been downgraded from ‘Strong Buy’ to ‘Hold’ following the failure of its KOASTAL-1 study for navacaprant in Major Depressive Disorder (MDD). Although enrollment for KOASTAL-2 and KOASTAL-3 studies in MDD has increased with topline data expected in Q2 2026, success is uncertain. The company’s NMRA-511 showed a promising signal for Alzheimer’s Disease agitation in a Phase 1b study, particularly in patients with elevated anxiety, but a Phase 2 study is not anticipated until Q1 2027, delaying near-term value realization.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.